1. Home
  2. Live Updates
  3. Merck research laboratories

Live Breaking News & Updates on Merck research laboratories

Stay informed with the latest breaking news from Merck research laboratories on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Merck research laboratories and stay connected to the pulse of your community

Final Trial Begins for World's First Skin Cancer Vaccine, Giving Hope to Those Affected

As this personalized mRNA vaccine enters its final trial phase, it brings promising prospects for individuals battling melanoma.

United-kingdom , British , Heather-shaw , Steve-young , Mufid-majnun , Iain-foulkes , Merck-research-laboratories , Cancer-research-united-kingdom , University-college-london-hospitals , Inno-flores , Tech-times , Data-breach

Merck highlights progress on HIV, hypertension, cervical cancer drugs

Merck got off to an excellent start in the first quarter of 2024.

New-jersey , United-states , Pennsylvania , China , America , South-east-asia , Caroline-litchfiield , Rob-davis , Human-health , Animal-health , European-medicines-agency , Merck-research-laboratories

Merck paying up to $208M to buy UB cancer research startup

Abceutics Inc., a startup preclinical-stage biopharmaceutical company spun out of a laboratory at the University at Buffalo, is being purchased as part of an up-to-$208 million agreement with biopharmaceutical giant

Michigan , United-states , Abceutic-pbses , Larry-wienkers , David-weinstock , Brandon-bordeau , Josephp-balthasar , Jane-chu , Department-of-pharmaceutical-sciences , Pfizer , National-institutes-of-health , Johnson

Merck acquires Abceutics in deal worth $208m to improve safety of ADCs

Merck acquires Abceutics in deal worth $208m to improve safety of ADCs
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Canada , Brandon-bordeau , Joseph-balthasar , David-weinstock , European-commission , Merck-co , National-institutes-of-health , Merck-research-laboratories , Buffalo-innovation-accelerator-fund , University-at-buffalo , National-institutes , Entrepreneur-partnerships

Phase 3 Trial Launches for Keytruda, MK-1084 in KRAS-Mutant NSCLC

A clinical trial has started to evaluate the investigational drug MK-1084 and Keytruda among some patients with metastatic non-small cell lung cancer.

Merck-research-laboratories , European-society-for-medical-oncology-congress , National-cancer-institute , Marjorie-green , Mutant-lung-cancer , European-society , Medical-oncology-congress , News , Lung-cancer , Nsclc , Kras-mutant-nsclc

Merck & Co. signs $280M deal for biotech to improve ADC safety

Merck & Co. signs $280M deal for biotech to improve ADC safety
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Michigan , United-states , Joseph-balthasar , David-weinstock , Daiichi-sankyo , Brandon-bordeau , University-of-michigan , Merck-research-laboratories , Merck-co , University-at-buffalo , New-jersey-based ,

Merck (MRK) Initiates Phase 3 Clinical Trial of MK-1084

Merck (MRK) Initiates Phase 3 Clinical Trial of MK-1084
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Canada , United-states , Taiho-pharmaceutical-co , Otsuka-pharmaceutical-co-ltd , European-society-for-medical-oncology , Merck-research-laboratories , Astex-pharmaceuticals-united-kingdom , Marjorie-green , Merck-research , European-society , Medical-oncology

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

Merck , known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in...

United-states , Canada , Merck-research-laboratories , European-society-for-medical-oncology , Exchange-commission , Statement-of-merck-co-inc , Linkedin , Taiho-pharmaceutical-co , Merck-co-inc , Astex-pharmaceuticals-united-kingdom , Instagram

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the...

Canada , Japan , Colombo , Western , Sri-lanka , United-states , America , Daiichi-sankyo , Raludotatug-deruxtecan , Mark-rutstein , European-society-for-medical-oncology-congress , Linkedin

Harpoon Therapeutics : April 3, 2024 -April 03, 2024 at 08:32 am EDT

BASKING RIDGE, N.J. & RAHWAY, N.J., April 3, 2024 - Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been...

Japan , Colombo , Western , Sri-lanka , Canada , United-states , America , Koji-ogiwara , Carly-myar , Peter-dannenbaum , Mark-rutstein , Jennifer-brennan